Left ventricular remodeling after acute myocardial infarction: Does eplerenone have an effect?

American Heart Journal

Volumn 157, Issue 6, 2009, Pages 1088-1096

  Weir, Robin A P ^a   Mark, Patrick B ^a   Petrie, Colin J ^a   Clements, Suzanne ^a   Steedman, Tracey ^a   Ford, Ian ^b   Ng, Leong L ^c   Squire, Iain B ^c   Wagner, Galen S ^d   McMurray, John J V ^a   Dargie, Henry J ^a  

^a WESTERN INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; BIOLOGICAL MARKER; DRUG DERIVATIVE; EPLERENONE; GELATINASE A; GELATINASE B; SPIRONOLACTONE;

AGED; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART INFARCTION; HEART VENTRICLE REMODELING; HUMAN; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

AGED; ALDOSTERONE ANTAGONISTS; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; SPIRONOLACTONE; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 67049118922     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.04.001     Document Type: Article

References (28)

1. Struthers AD. The clinical implications of aldosterone escape in congestive heart failure. Eur J Heart Fail 2004;6:539-45. (Pubitemid 39070505)
2. Mc Kelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Rando-mized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilotstudy. Circulation 1999;100:1056-64. (Pubitemid 29416231)
3. Borghi C, Boschi S, Ambrosioni E, etal. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myo-cardial infarction treated with ACE inhibitors. J Clin Pharmacol 1993; 33:40-5. (Pubitemid 23067505)
4. Begyui F, Collet JP, Benoliel JJ, etal. High plasmaaldosteronelevels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 2006;114:2604-10.
5. Pitt B, Zannad F, Remme WJ. The effects of spironolactone on morbidity and mortality in patients with severe heart failure. Randomised Aldactone Evaluation Study Investigators. N Engl J Med 1999;4341:709-17. (Pubitemid 29407370)
6. Pitt B, Remme WJ, Zannad F, etal. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21. (Pubitemid 36384098)
7. Wang W. Chronic administration of aldosterone suppresses baror-eceptor reflex function in the dog. Hypertension 1994;24:571-5. (Pubitemid 24337826)
8. Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-65.
9. Rocha R, Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002;283:H1802-10. (Pubitemid 35217013)
10. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993;25:563-75. (Pubitemid 23208145)
11. De Angelis N, Fiordaliso F, Latini R, et al. Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. J Mol Cell Cardiol 2002;34:1655-65. (Pubitemid 35454480)
12. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001;103:72-7. (Pubitemid 32050438)
13. Hayashi M, Tsutamoto T, Wada A, et al. Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction. Circulation 2003;107:2559-65. (Pubitemid 36628936)
14. Suzuki G, Morita H, Mishima T, et al. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 2002;106:2967-72. (Pubitemid 35424750)
15. Fraccarollo D, Galuppo P, Hildemann S, et al. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 2003;42:1666-73. (Pubitemid 37378451)
16. Delyani JA, Robinson EL, Rudolph AE. Effect of a selective aldosterone receptor antagonist in myocardial infarction. Am J Physiol Heart Circ Physiol 2001;281 :H647-54.
17. Cleland JG, Coletta AP, Clark AL. Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet. Eur J Heart Fail 2007;9:740-5.
18. Cleland JG, Coletta AP, Abdellah AT, et al. Clinical trials update from Heart Rhythm 2007 and Heart Failure 2007: CARISMA, PREPARE, DAVID II, SAVE-PACE, PROTECT and AREA-IN-CHF. Eur J Heart Fail 2007;9:850-3. (Pubitemid 47212838)
19. Chan AK, Sanderson JE, Wang T, et al. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure. J Am Coll Cardiol 2007;50: 591-6. (Pubitemid 47199012)
20. Rohde LE, Ducharme A, Arroyo LH, et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experi-mental myocardial infarction in mice. Circulation 1999;99:3063-70. (Pubitemid 29270438)
21. Alfakih K, Plein S, Thiele H, et al. Normal human left and right ventriculardimensions for MRI as assessed byturbo gradientechoand steady-state free precession imaging sequences. J Magn Reson Imaging 2003;17:323-9. (Pubitemid 36259246)
22. White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987;76:44-51. (Pubitemid 17093191)
23. Abdulla J, Barlera S, Latini R, et al. A systematic review: effect of angiotensin converting enzyme inhibition on left ventricular volumes and ejection fraction in patients with a myocardial infarction and in patients with left ventricular dysfunction. Eur J Heart Fail 2007;9: 129-35. (Pubitemid 46394070)
24. Ferrari R. Perindopril and Remodeling in Elderly with Acute Myocardial Infarction Investigators Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodeling and clinical outcome: results of the randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) study. Arch Intern Med 2006; 166:659-66.
25. Silvestre JS, Heymes C, Oubénaïssa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effectof angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99:2694-701. (Pubitemid 29237459)
26. Matsunaga T, Abe N, Kameda K, et al. Circulating level of gelatinase activity predicts ventricular remodeling in patients with acute myocardial infarction. Int J Cardiol 2005;105:203-8. (Pubitemid 41512488)
27. Squire IB, Evans J, Ng LL, et al. Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardio-graphic and neurohumoral parameters of leftventricular dysfunction. J Card Fail 2004;10:328-33. (Pubitemid 39092685)
28. Kelly D, Cockerill G, Ng LL, et al. Plasma matrix metalloprotei-nase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 2007; 28:711-8. (Pubitemid 46439245)